<?xml version="1.0" encoding="UTF-8"?>
<p>The guidelines for the “Appropriate Use of Herbal Medicines” (
 <xref rid="B475" ref-type="bibr">WHO, 1998</xref>, p. 2) state that “it is necessary to make a systematic inventory and assessment (preclinical and clinical) of medicinal plants; to introduce measures on the regulation of herbal medicines to ensure quality control of herbal products by using modern techniques, applying suitable standards and good manufacturing practices; and to include herbal medicines in the national standard or pharmacopoeia.” A relatively cost-effective way for conducting clinical trials are retrospective treatment-outcome studies (RTO studies), which use questionnaires for the collection of information from a representative sample of the population (
 <xref rid="B200" ref-type="bibr">Graz et al., 2005</xref>; 
 <xref rid="B201" ref-type="bibr">Graz et al., 2007</xref>). RTO studies assess retrospectively the effectiveness of herbal preparation and treatments for defined medical syndromes and clinical manifestations (
 <xref rid="B200" ref-type="bibr">Graz et al., 2005</xref>; 
 <xref rid="B482" ref-type="bibr">Willcox et al., 2011</xref>). While the case of 
 <italic>Aristolochia</italic> spp. derived products showcases that herbal drugs are not always safe, those with a traditional clinical track record and above all food items, usually considered safe, qualify for RTO studies (
 <xref rid="B475" ref-type="bibr">WHO, 1998</xref>; 
 <xref rid="B482" ref-type="bibr">Willcox et al., 2011</xref>).
</p>
